Helen Collins
About Helen Collins
Chief Medical Officer Helen Collins' Career Overview
Helen Collins currently serves as the Chief Medical Officer. She has a robust career in the medical and biotechnology sectors, having held numerous high-ranking positions in top industry organizations. Notably, she was the Chief Medical Officer and Executive Vice President at Five Prime Therapeutics, focusing on oncology.
Helen Collins' Educational Background and Medical Training
Helen Collins earned her M.D. from the renowned Johns Hopkins University School of Medicine. She holds an A.B. in Chemistry from Bryn Mawr College. She completed her residency in internal medicine at Johns Hopkins Hospital, followed by a fellowship at Stanford University School of Medicine with a concentration in gastrointestinal cancer.
Helen Collins' Role in Oncology and Biotechnology
Helen Collins has considerable expertise in oncology, highlighted by her board certification in the field. She advanced professionally at Gilead Sciences, Inc., culminating as Program and Clinical Lead for BTK and BET inhibitor programs. At Amgen, she took on increasing responsibilities, ultimately serving as Global Lead for Oncology Biosimilars.
Helen Collins' Clinical Practice Experience
Helen Collins practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group. Additionally, she served as President of the group for three years, demonstrating her leadership capabilities in clinical practice settings.
Helen Collins' Board Membership at Kura Oncology
Helen Collins serves on the board of directors for Kura Oncology. Her extensive background in oncology and her experiences at companies like Gilead Sciences, Amgen, and Five Prime Therapeutics offer valuable insights to Kura Oncology's board.